SCHEMBL8293271

SCHEMBL8293271

CC1NC(=O)c2ccccc2C1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.48
GSK3B P49841 1/20 0.46
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
S100A4 P26447 1/20 0.43
POLB P06746 1/20 0.43
TNKS2 Q9H2K2 5/20 0.41
PBRM1 Q86U86 1/20 0.41
CASP3 P42574 1/20 0.40
CASP2 P42575 1/20 0.40
CASP7 P55210 1/20 0.40
CASP6 P55212 1/20 0.40
CASP8 Q14790 1/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
HTR2B P41595 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13847518 0.80 CREBBP (0.55) TSHRGSK3BTNKS2PBRM1LMNA
SCHEMBL19573959 0.78 TNKS2 (0.49) TSHRGSK3BKMT2ATNKS2PBRM1
SCHEMBL19573960 0.78 TNKS2 (0.49) TSHRGSK3BKMT2ATNKS2PBRM1
SCHEMBL31667419 0.78 TNKS2 (0.49) TSHRGSK3BKMT2ATNKS2PBRM1
SCHEMBL29695366 0.78 TNKS2 (0.49) TSHRGSK3BKMT2ATNKS2PBRM1
SCHEMBL1708832 0.78 TNKS2 (0.49) TSHRGSK3BKMT2ATNKS2PBRM1
SCHEMBL677629 0.76 MEN1 (0.55) MEN1KMT2AS100A4POLBLMNA
SCHEMBL22011499 0.74 GSK3B (0.46) TSHRGSK3BMEN1KMT2AS100A4
SCHEMBL12646072 0.74 MEN1 (0.52) MEN1KMT2AS100A4POLBLMNA
SCHEMBL5063195 0.72 BRPF1 (0.67) TSHRGSK3BKMT2APOLBTNKS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2332912-A1 Heteroarylaminosulfonylphenylderivates for use as sodium or calcium channel blockers in the treatment of pain VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-15 EP disclosed
EP-2327701-A1 Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-01 EP disclosed
WO-2005013914-A2 HETEROARYLAMINOSULFONYLPHENYL DERIVATIVES FOR USE AS SODIUM OR CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-02-17 WO disclosed